How Do Mouse Monoclonal Antibodies to CD353 Support Cancer Research?

Cells are the basic structural and functional units of life. They work in a highly controlled and organized way. Each cell has mechanisms that tell it when to grow, divide, perform its function, repair damage, or die. However, when the mechanisms of cell growth, divide, and die disrupts, cells may begin to grow and divide uncontrollably.

These abnormal cells can accumulate and form a mass of tissue called a tumor. If the abnormal cells invade surrounding tissues or spread to other parts of the body, it can develop into cancer.

So, cancer can be defined as a group of diseases in which abnormal cells grow and divide uncontrollably. It develops when genetic changes disrupt these normal controls, allowing cells to continue multiplying.

Cancer does not have one single cause. Factors that can increase cancer risk include:

• Genetic mutations inherited from parents
• Tobacco use
• Certain infections
• Ultraviolet radiation
• Excessive exposure to some chemicals
• Alcohol consumption
• Obesity and certain metabolic factors
• Increasing age
• Some environmental exposures

Since it is a life-threatening disease, it is crucial to diagnose and treat it at an early stage. Here is where a mouse monoclonal antibody to CD353 comes into play.

What is Mouse Monoclonal Antibody to CD353?

A mouse monoclonal antibody to CD315 is a laboratory-produced antibody made by mouse immune cells. It is designed to recognize and bind specifically to CD353.

CD353, also known as BLAME or SLAMF8 (Signaling Lymphocytic Activation Molecule Family Member 8), is a cell-surface protein that belongs to the CD2 family. It is involved in immune-cell regulation.

While it lacks typical intracellular signaling motifs, it can influence immune-cell behavior through noncanonical mechanisms. Tumor-associated macrophages (TAMs) can adopt phenotypes that support tumor growth and suppress antitumor immunity.  SLAMF8 is predominantly expressed in macrophages within several tumor environments, including colorectal cancer. Higher macrophage-associated SLAMF8 expression has also been associated with poorer outcomes in colorectal cancer research models and patient cohorts.

That is why it is an important target that contributes to the investigation of tumor-associated immune responses.

How SLAMF8 Helps in Cancer Research?

Detect CD353 Expression in Cancer Models

Researchers use mouse monoclonal antibodies to CD353 to detect the presence and distribution of the protein. They use these antibodies in various techniques such as:

• Western blotting
• Flow cytometry
• Immunohistochemistry (IHC)
• Immunofluorescence (IF)
• Immunocytochemistry (ICC)

Flow cytometry helps researchers determine the percentage of CD353-positive cells within a heterogeneous tumor or immune-cell population. IHC and IF provide spatial information, which further helps researchers determine whether CD353-positive cells are concentrated within particular regions of tumor tissue.

This information helps study the relationship between CD353 expression and macrophage infiltration.

Study Tumor-Associated Macrophages

TAMs are an important component of many solid tumors. Depending on signals in their surrounding environment, macrophages can acquire different functional states. Some macrophage populations can promote inflammation and antitumor activity, while others can exhibit immunosuppressive, tumor-supporting characteristics.

As already discussed, SLAMF8 is usually associated with macrophage behavior in cancer. In colorectal cancer models, elevated SLAMF8 expression was associated with an immunosuppressive macrophage phenotype, while inhibition of SLAMF8 promoted changes in the tumor immune environment and increased cytotoxic CD8+ T-cell activity.

So, researchers use mouse monoclonal antibodies against CD353 to identify CD353-positive macrophages and investigate how their abundance or phenotype changes under different experimental conditions.

Investigate Macrophage Polarization

Researchers use CD353 antibodies to investigate macrophage polarization, which further contributes to cancer research.

Researchers examine CD353 expression alongside macrophage markers such as F4/80, CD68, CD86, or CD206. They combine these markers to characterize macrophage populations and determine whether CD353 expression is associated with particular macrophage phenotypes.

It has been found that SLAMF8 promotes macrophage polarization toward an M2-like immunosuppressive state through pathways including PI3K/AKT and JAK/STAT3 during colorectal cancer research. Inhibition of SLAMF8 was associated with increased M1-like macrophages and enhanced cytotoxic CD8+ T-cell infiltration.

This study clearly demonstrates that antibodies targeting CD353 can be valuable for investigating macrophage biology within tumors.

Support Tumor Microenvironment Research

Cancer cells do not function independently. Immune cells, fibroblasts, blood vessels, cytokines, extracellular matrix components, and other elements of the TME influence their behavior.

Researchers use CD353 antibodies to map the distribution of SLAMF8-positive immune cells within tumor tissues. When combined with multiplex immunofluorescence or other multi-marker approaches, this can help researchers investigate relationships between CD353-positive macrophages and tumor cells or T lymphocytes.

Explore Immune Evasion and Immunotherapy

Immune evasion is a major challenge in cancer treatment. Tumors can create an immunosuppressive environment that limits the ability of immune cells to recognize and eliminate malignant cells.

At times, SLAMF8 turns out to be a potential immune-regulatory molecule. Research in colorectal cancer has suggested that increased SLAMF8 activity in TAMs can contribute to immunosuppression and CD8+ T-cell dysfunction. In experimental models, inhibiting SLAMF8 remodeled the tumor microenvironment and improved sensitivity to anti-PD-1 therapy.

Researchers use mouse monoclonal antibodies to CD353 to measure CD353 expression before and after experimental treatments. This can help determine whether changes in CD353-positive immune-cell populations correlate with treatment responses.

What to Check Before You Order a CD353 Antibody

Antibody performance varies between clones, applications, and sample types, so the reagent you choose shapes the quality of your data. A few checks before purchase can save a great deal of troubleshooting later.

• Species reactivity: confirm the antibody is validated for the species in your model, since human SLAMF8 and mouse Slamf8 are not always cross-reactive.
• Validated applications: a clone validated for flow cytometry will not necessarily perform in IHC on formalin-fixed tissue. Check the datasheet application by application.
• Immunogen and epitope: extracellular epitopes are needed for surface staining on live cells, while intracellular or denatured epitopes may suit Western blotting.
• Clone, isotype, and format: note the clone ID for reproducibility, and choose unconjugated or fluorophore-conjugated formats to fit your panel.
• Validation evidence: look for knockdown or knockout controls, positive and negative tissue staining, and independent citations rather than representative images alone.
• Controls and lot consistency: plan isotype and secondary-only controls, and ask the supplier about lot-to-lot testing for long-running studies.

Suppliers that publish full datasheets, validation data, and citation lists make these checks straightforward, and their technical support teams can usually advise on protocols for your specific model.

Disclaimer